AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
13.05
+0.09 (0.69%)
At close: Nov 20, 2024, 4:00 PM
12.96
-0.09 (-0.69%)
After-hours: Nov 20, 2024, 7:02 PM EST

Company Description

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally.

The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

AVITA Medical, Inc.
AVITA Medical logo
Country United States
Founded 2020
Industry Medical Devices
Sector Healthcare
Employees 207
CEO James Corbett

Contact Details

Address:
28159 Avenue Stanford, Suite 220
Valencia, California 91355
United States
Phone 661 367 9170
Website avitamedical.com

Stock Details

Ticker Symbol RCEL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001762303
CUSIP Number 05380C102
ISIN Number US05380C1027
Employer ID 20-2578762
SIC Code 3841

Key Executives

Name Position
James M. Corbett Chief Executive Officer, President and Executive Director
David O'Toole Chief Financial Officer
David Fencil Senior Vice President of Global Operations
Dr. Katie Bush Ph.D. Senior Vice President of Scientific and Medical Affairs
Jessica Ekeberg Investor Relations Executive
Nicole Linda Kelsey Chief Legal and Compliance Officer and Corporate Secretary
Debbie Garner Senior Vice President of Global Marketing and Strategy
Rob Hall Senior Vice President of Human Resources
Dr. Niraj Doshi J.D., P.M.P., Ph.D. Senior Vice President of Product Development and Program Management
Ron Lagerquist Senior Vice President of Quality Assurance and Regulatory Affairs

Latest SEC Filings

Date Type Title
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Aug 8, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 31, 2024 8-K Current Report
Jul 1, 2024 8-K Current Report
Jun 6, 2024 8-K Current Report
May 30, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report